WINT_OUT_1 [2025-03-20 09:13:43 -0400] 2129 Bytes | 558 tokens | Cum: 558 tkns (6.98% of 8k)
==========================================================================

Alright, let’s light it up, because it's 09:13:41 AM on Thursday March 20, 2025 ET (UTC-0400), and I'm charging into Windtree Therapeutics (WINT), popping from 1.69 to 2.69. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for Windtree Therapeutics:

C1 - Today 08:27AM - Windtree shares rise as it announces agreement to become sourcing partner for Evofem
C2 - 08:00AM - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
C3 - Mar-04-25 08:00AM - Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure
C4 - Feb-27-25 08:00AM - Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India
C5 - Feb-18-25 08:00AM - Windtree Therapeutics, Inc. Announces Reverse Stock Split
C6 - Feb-12-25 08:00AM - Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference
C7 - Jan-15-25 08:00AM - Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline
C8 - Jan-13-25 08:00AM - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Windtree Therapeutics (WINT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

WINT_OUT_3 [2025-03-20 09:13:50 -0400] 976 Bytes | 271 tokens | Cum: 831 tkns (10.39% of 8k)
==========================================================================

Showing C2 (chunk 1 of 10): C2:
**Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product**
Date: 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046178/0/en/Windtree-Announces-License-and-Supply-Agreement-to-Become-Sourcing-Partner-for-a-Small-Biotech-with-an-FDA-Approved-Product.html

March 20, 2025 08:00 ET| Source:Windtree TherapeuticsWindtree Therapeutics

WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing partner for Evofem Biosciences, Inc. (OTCQB: EVFM) fo

-- More? (MOR) or Next section? (NEX)

WINT_OUT_5 [2025-03-20 09:13:52 -0400] 1039 Bytes | 291 tokens | Cum: 1211 tkns (15.14% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T12:21:04Z - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with ...
A2 - 2025-03-20T12:09:53Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Aditxt (NASDAQ:ADTX), AEON Biopharma...
A3 - 2025-03-20T12:21:09Z - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with ...
A4 - 2025-03-20T12:06:04Z - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with ...
A5 - 2025-03-04T13:17:50Z - Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acut...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

WINT_OUT_7 [2025-03-20 09:13:53 -0400] 968 Bytes | 257 tokens | Cum: 1470 tkns (18.38% of 8k)
==========================================================================

Showing A1 (chunk 1 of 10): A1:
**Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product**Date: 2025-03-20Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/03/20/tmt-newswire/globenewswire/windtree-announces-license-and-supply-agreement-to-become-sourcing-partner-for-a-small-biotech-with-an-fda-approved-product/2076976Transaction is part of the Company's new corporate strategy to become a revenue generating biotech

WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agre

-- More? (MOR) or Next section? (NEX)

WINT_OUT_9 [2025-03-20 09:13:55 -0400] 969 Bytes | 229 tokens | Cum: 1701 tkns (21.26% of 8k)
==========================================================================

Showing A1 (chunk 2 of 10): ement to become the sourcing partner for Evofem Biosciences, Inc. (OTCQB: EVFM) for one of Evofem's FDA-approved products -- PHEXXI® (lactic acid, citric acid and potassium bitartrate). The product is a first-in-class hormone-free, on-demand prescription contraceptive vaginal gel that women control. PHEXXI annual revenues have grown to more than $19 million with more than 96,000 boxes of 12 pre-filled applicators sold in full year 2024.

Windtree has manufacturing contacts that we believe are capable of reducing pharmaceutical product cost of goods for PHEXXI. Pursuant to the License and Supply Agreement, Windtree will serve as the sourcing partner to Evofem and aims to help generate profitable revenue by contracting with the manufacturer to produce PHEXXI at a cost that is significantly below current levels. Evofem will maintain ownership of the asset and continue to commercialize PHEXX

-- More? (MOR) or Next section? (NEX)

WINT_OUT_11 [2025-03-20 09:13:57 -0400] 998 Bytes | 294 tokens | Cum: 1997 tkns (24.96% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-13T13:00:00Z - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
B2 - 2024-12-09T13:00:00Z - Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
B3 - 2024-07-10T22:16:16Z - Eagle Point Income reports NAV per share and quarterly earnings By Investing.com - Investing.com
B4 - 2024-04-18T12:00:00Z - Windtree Therapeutics Announces Reverse Stock Split
B5 - 2024-04-08T20:48:00Z - Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
B6 - 2024-02-01T13:00:00Z - Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

WINT_OUT_13 [2025-03-20 09:14:03 -0400] 580 Bytes | 140 tokens | Cum: 2139 tkns (26.74% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Eagle Point Income reports NAV per share and quarterly earnings By Investing.com - Investing.com**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/news/company-news/windtree-therapeutics-secures-200000-in-private-notes-93CH-3514739Windtree Therapeutics, a biotechnology firm, has secured $200,000 in private notes, including senior secured and unsecured promissory notes. The company has also seen recent developments such as a reverse stock split and securing new financing options.

-- More? (MOR) or Next section? (NEX)

WINT_OUT_15 [2025-03-20 09:14:04 -0400] 1163 Bytes | 311 tokens | Cum: 2551 tkns (31.89% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-02-18 8-K Item 7.01. Regulation FD Disclosure.

On February 18, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1 atta...

S2 - 2025-02-18 8-K Item 7.01. Regulation FD Disclosure.

On February 18, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1 atta...

S4 - 2024-11-27 8-K Item 2.02

Results of Oper and Fin Cond

On November 27, 2024, Windtree Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2024 . A copy of the press release is furnished as Exhibit 99.1 ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

WINT_OUT_17 [2025-03-20 09:14:11 -0400] 919 Bytes | 217 tokens | Cum: 2770 tkns (34.62% of 8k)
==========================================================================

Showing S4 (chunk 1 of 1): S4:
Item 2.02

Results of Operations and Financial Condition

On November 27, 2024, Windtree Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2024 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing....

-- More? (MOR) or Next section? (NEX)

WINT_OUT_19 [2025-03-20 09:14:27 -0400] 4343 Bytes | 1228 tokens | Cum: 4138 tkns (51.73% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| Volume: 110,879 | SMA50: -73.90% | Market Cap: 1.18M | Option/Short: No / No | Sales past 5Y: -25.00% | Sales Surprise: - |
+---------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 350.17K | SMA200: -98.65% | Shs Outstand: 0.75M | Short Float: 11.07% | Employees: 15 | EPS Surprise: - |
+---------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.31 | Perf Week: -17.16% | Shs Float: 0.75M | Short Ratio: 0.24 | Debt/Eq: 1.68 | P/E: - |
+---------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 20.58 | Perf Month: -69.24% | Inst Own: 0.84% | Short Interest: 0.08M | Sales Y/Y TTM: - | Earnings: Nov 27 AMC |
+---------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.63 | Perf Quarter: -90.44% | Insider Own: 0.13% | Beta: 0.82 | ROE: -138.34% | |
+---------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -36.25% | Index: - | Insider Trans: - | Sales Q/Q: - | ROI: -146.00% | |
+---------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

No transactions recorded.

Now we've reached the end of the analysis.
You are now invited to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
Again, that is: 1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

[Company Financial Summary]
[Company Details]
Name: Windtree Therapeutics, Inc. Common Stock
Market Cap: 1266386.29
Shares Outstanding: 749341
Sector: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -2749000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.69
Average Volume: 568195.73
30-Day High: 5.495
30-Day Low: 1.69

[Detailed Financials: Q3 2024]
- Total Assets: $30,448,000.0
- Total Liabilities: $23,897,000.0
- Total Equity: $4,409,000.0
- Current Assets: $3,928,000.0
- Current Liabilities: $14,426,000.0

[Income Statement: Q3 2024]
- Revenue: $0
- Net Income: $-2,749,000.0
- Operating Income: $-4,741,000.0
- Earnings Per Share (EPS): -4.23

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: N/A

[Detailed Financials: Q1 2024]
- Total Assets: $30,103,000.0
- Total Liabilities: $14,682,000.0
- Total Equity: $15,421,000.0
- Current Assets: $3,339,000.0
- Current Liabilities: $4,985,000.0

[Income Statement: Q1 2024]
- Revenue: $0
- Net Income: $10,219,000.0
- Operating Income: $-4,405,000.0
- Earnings Per Share (EPS): 21.98

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

WINT_OUT_21 [2025-03-20 09:14:28 -0400] 561 Bytes | 131 tokens | Cum: 4497 tkns (56.21% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

WINT_IN_23 [2025-03-20 09:14:29 -0400] 126 Bytes | 29 tokens | Cum: 4533 tkns (56.66% of 8k)
==========================================================================

====================================
[2025-03-20 06:14:29] # Analysis Completed
Elapsed Time: 48.52 seconds